
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc. demonstrates a strong outlook due to the promising results of its product Arakoda, which achieved an 80% cure rate in a clinical case series for patients with persistent babesiosis who did not respond to previous treatments. The drug's advantages, such as a convenient dosing regimen, good tolerability, and lack of drug resistance reports, position it favorably in the competitive malaria prophylaxis market. Furthermore, the initiation of the expanded access clinical study for Arakoda indicates ongoing commitment to advancing its pipeline, which could positively impact future earnings per share estimates.
Bears say
60 Degrees Pharmaceuticals Inc is facing financial strain due to the necessity of paying deferred offering costs related to its proposed offerings, which suggests a reliance on capital raising for operational liquidity. Additionally, the company operates in a highly competitive specialty pharmaceutical market, where ongoing research and development expenses may strain its financial resources without guaranteed successful outcomes. With a focus on infectious diseases, the company's pipeline may also be negatively impacted by external factors such as market competition and regulatory challenges, further contributing to a cautious financial outlook.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares